+34 679 490 537info@nanbiosis.com

Nanbiosis

U1. Protein Production Platform Unit (PPP)

Ciber bbn

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB
Order request

Description

The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit is also applying for the ISO9001 certification forstandard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Active projects

TitleFundin: OrganismCall: Funding source Role
GA: 720942SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-FabryUnión Europea (Comisión Europea)H2020-NMBP-2016-2017Coordinator
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Coordinator

Other projects

RefTitleFunding OrganismUnit Role
PI15/00272Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer.Instituto de Salud Carlos IIIParticipant
BIO2013-41019-PENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDSMINECOParticipant
2014SGR-132Basic and Applied MicrobiologyAGAURParticipant
BIO2016-76063-RDEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERESMINECOWorking package
RTC-2014-2207-1TERARMET: Development of therapies for the treatment of rare congenital metabolic diseasesMINECOParticipant
Marato 416/C/2030TV32013-132031Genotoxic nanoparticles targeting colorectal cancer stem cellsMarato TV3Participant

Publications

2016

  • Corchero J.L.. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
  • Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
  • Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U1

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

25 Feb

An Auristatin-based nanoconjugate reduces leukemia burden in a disseminated AML model

Researchers of the Nanotoxicology Unit of the the CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), leaded by Ramon Mangues and Isolda Casanova at the Research Institute of the Hospital de Sant Pau and of the NANBIOSIS (nanbiosis.es) Protein Platform (u1-protein-production-platform-ppp) leaded by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have developed a novel protein-Auristatin nanoconjugate that specifically targets CXCR4-overexpressing acute myeloid leukemia (AML) cells. It selectively accumulates in target cancer cells expressing this receptor and deliver the toxin Auristatin within their cytosol. There, Auristatin potently blocks microtubule polymerization, provoking mitotic catastrophe,[...]

21 Feb

A nanotoxin targeting the receptor CXCR4 blocks lymphoma dissemination

Researchers at the Nanotoxicology Unit of CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), led by Ramon Mangues and Isolda Casanova of the Research Institute at the Hospital de Sant Pau and the Researchers of the NANBIOSIS (nanbiosis.es) Protein Production Platform (u1-protein-production-platform-ppp) led by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have participated in the development of a novel protein nanoparticle that incorporates the Exotoxin of the bacteria Pseudomonas aeruginosa, capable of targeting lymphoma cells that overexpress the CXCR4 receptor. They internalize selectively in target cancer cells through CXCR4 receptor-mediated endocytosis du[...]

15 Feb

Identification of a novel nanotherapy active in cancer cells resistant to chemotherapy

Researchers of the Nanotoxicology Unit (u18-nanotoxicology-unit) led by Ramon Mangues and Isolda Casanova at the Research Institute of the Hospital de Sant Pau and the Protein Production Platform (u1-protein-production-platform-ppp), led by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, both belonging to the ICTS NANBIOSIS (nanbiosis.es) of the CIBER-BBN, have participated in the production of a novel Nanotoxin capable of selectively killing cancer cells which became resistant to chemotherapy. Development of cancer resistance frequently associates with the overexpression of the CXCR4 receptor. It is known that chemotherapy kills cancer[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

04 Feb

Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles

In the frame of the collaboration of three units of NANBIOSIS, researchers of CIBER-BBN Groups proposed a strategy to simultaneously deliver anticancer drug pairs, composed by a tumor-targeted protein nanoparticle and an antiproliferative drug, with specific activ-ity for the same type of cancer. These three units are: NANBIOSIS U1 Protein Production Platform (PPP), at IBB-UAB, led by Toni Villaverde y Neus Ferrer NANBIOSIS U18 of Nanotoxicology Unit, at Institut de Recerca. Hospital de la Santa Creu i Sant Pau, led by Ramón Manques and Isolda Casanova, and NANBIOSIS U29 Oligonucleotide Synthesis Platform (OSP) at IQAC_CSIC, led by Ramón Eritja and[...]

27 Jan

Smart-4-Fabry final workshop

Next Wedneday, February 3, 2021 will take place the on-line event Smart-4-Fabry Final Workshop.   Smart-4-Fabry is a european project, coordinated by CIBER-BBN wich has been developed during four years. This project is a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages. This project is also a clear example of the relevance of access to advanced research infrastructures as NANBIOSIS -ICTS. Four NANBIOSIS units have collaborated and contributed to Smart-4-Fabry development: U1 Protein Production Platform (PPP) at IBB-UABU3 Synthesis of Peptides Unit at IQAC-CSICU6 Biomaterial Processing and Nanostructuring Unit at ICMAB-CSICU20 In Vivo[...]

17 Aug

The Autonomous University of Barcelona, in the elite of the 300 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world and the first of the Spanish universities. This indicator organizes up to 20,000 university centers worldwide, based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings The Autonomous University of Barcelona houses two of NANBIOSIS Units: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Paolo Saccardo, offer an “tailored”[...]

U1-Protein Production Platform - PPP
Read More

U2. Custom Antibody Service Unit (CAbS)

U2 CAbS-hybridoma clone
Ciber bbn

U2. Custom Antibody Service (CAbS)

  • Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
  • Scientific Coordinator: Dra. Nuria Pascual npdqob@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus.Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
PIE1400061 Molecular links between diabetes and neurodegenerative diseases ISCIII Oberver
2014SGR1484 Consolidated Research Group Generalitat de Catalunya Participant
FP7-614168 Real time monitoring of SEA contaminants by an autonomous Lab-on-a-Chip biosensor (SEA-on-a-CHIP) European Commission Oberver
CI16-00031 Caixa Impulse A new approach for the detection of Pseudomonas aeruginosa CaixaBank Participant
MSCA-ITN2015-675412 New Diagnostics for Infectious Diseases European Commission Participant
TECCTP15-1-0011 Ajuda acreditació Tecnio del grup Nb4D ACCIÓ: Generalitat de Catalunya Others

Publications


2016

  • Roncador G., Engel P., Maestre L., Anderson A.P., Cordell J.L., Cragg M.S. et al. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. 2016;8(1):27-36.
  • Pastells C., Pascual N., Sanchez-Baeza F., Marco M.-P.. Immunochemical Determination of Pyocyanin and 1-Hydroxyphenazine as Potential Biomarkers of Pseudomonas aeruginosa Infections. Analytical Chemistry. 2016;88(3):1631-1638.
  • Salvador J.-P., Marco M.-P.. Amperometric Biosensor for Continuous Monitoring Irgarol 1051 in Sea Water. Electroanalysis. 2016;28(8):1833-1838.

News U2

06 Apr

A GLOBAL VISION OF THE COVID-19 PANDEMIC by CSIC

A report from the Spanish National Research Council (CSIC) collects in open access the results of a year of research on SARS-CoV-2. The book ‘A global vision of the COVID-19 pandemic’ shows the responses and solutions obtained by the 300 research teams of the CSIC Global Health Platform. The Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) has participated in the preparation of the chapter ‘Actions in containment and diagnosis’: Specific mucosal protection against the entry of SARS-CoV-2 – Lluisa Coderch. The role of diagnosis in the face of the pandemic – by M.-Pilar Marco, Scientific Director of NANBIOSIS U2 Custom[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

07 Jan

NANBIOSIS Unit 2 obtains the Biosafety Level 2 Accreditation

The laboratory of NANBIOSIS Unit 2 from IQAC-CSIC and CIBER-BBN has obtained the biosafety level 2 accreditation, which allows the laboratory to work with biological agents classified in the risk group 2. Biological containment level 2 (NBS2) laboratories are generally required to work with any derivative of human blood or other primates, body fluids (especially when they are visibly contaminated with blood), cell lines, or tissues in which has uncertainty about the presence of an infectious agent. Also, the group participates in the COVID project “Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV)”, funded by the CSIC. This project[...]

11 Dec

Highly sensitive monoclonal antibodies for a new biosensor for hormones detection in fertility treatments

Nb4D research group and NANBIOSIS U2 Custom Antibody Service (CAbS) of CIBER-BBN at the IQAC-CSIC, together with the company Droplite Technologies have obtained a Retos-Collaboration project funded by the Ministry of Science and Innovation, for the development of a biosensor for detection and rapid quantification of hormones, linked to in-vitro fertility treatments. NANBIOSIS U2 CAbS will be responsible for the production of highly sensitive monoclonal antibodies, counting on the experience in this field of Juan Pablo Salvador, project coordinator, Núria Pascual and Mª Pilar Marco. The measurement of the hormone estradiol is a key indicator, both of maturity and of[...]

29 Nov

Nb4D group- NANBIOSIS U2 receives the acreditation TECNICO, in the on line event organizes by ACCIO

Las November 27 was held the ACCIO ceremony (on line this year due to the Covid Pandemic restrictions) of disclosure of new TECNIO accreditations. Aurea Rodriguez, Director of Business Innovation at ACCIO has welcomed the attendees to the event. Later, the TECNIO program Coordinator, Marta Peidro, presented the background and rationale for this accreditation for excellence groups in technology transfer in Catalonia. This year there have been five new groups from among all Catalan universities and research organizations, which have obtained the TECNIO accreditation for the first time, making a total of fifty-four groups accredited in 2020. The event continued[...]

13 Nov

Nb4D group – NANBIOSIS Unit 2 CAbS – accredited with the TECNIO seal

The Nb4D group of CIBER-BBN and IQAB-CSIC, coordinator of NANBIOSIS Unit 2 Custom Antibody Service (CAbS), has been accredited with the TECNIO seal. This accreditation is the hallmark TECNIO granted by the Government of Catalonia, through ACCIÓ, to identify the developers and facilitators of differential technologies in Catalonia. TECNIO is the umbrella brand for catalan technology centres and university research groups dedicated to industrial research and technology transfer. ACCIO, CERTIFICATION, QUALITY MANAGEMENT SYSTEM[...]

02 Nov

Prof. Pilar Marco, in the program “Meridiano Turing” of RTVE explains the COVID-19 tests.

The last edition of the program “Meridiano Turing” of RTVE interviews Maria Pilar Marco Head of CIBER-BBN and IQAC-CSIC group Nb4D and NANBIOSIS-ICTS Unit 2 Custom Antibody Service (CAbS), Cesar Fernández (Head of the Chemical Transducers Group at IMB-CNM, CSIC) and María Cruz Minguillón (EGAR group at IDAEA) Pilar Marco y César Fernández, the authors of the block of the CSIC’s report entitled “Containment and diagnosis“, explain wich is the best way to diagnose COVID and how reliable are the tests in this moment. What is needed is to detect an infection -says Pilar Marco- is viral material and w[...]

02 Oct

New updated version of the CSIC report on COVID-19

The report by Spanish Higher Council for Scientific Research (CSIC) summarizng the most relevant scientific results on the Covid-19 pandemic.  “A global vision of the Covid-19 pandemic: What we know and what we are investigating from CSIC”, has just published its version number 4. This report is structured in five blocks: prevention, disease, containment and diagnosis, treatment and vaccines, and global impact. The containment and diagnosis block describes how the virus is transmitted in the air indoors and the analysis of wastewater as a system for early detection of SARS-CoV-2 is explained. In addition, the importance of diagnosis in t[...]

U2-Custom Antibody Service (CAbS)
Read More

U3. Synthesis of Peptides Unit

Ciber bbn

U3. Synthesis of Peptides Unit

  • Scientific Director: Prof. Fernando Albericio albericio@ub.edu
  • Scientific Coordinator: Dr. Miriam Royo miriam.royo@iqac.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request

This Unit is coordinated by the Peptides and Nanoparticles Group at the Parc Científic de Barcelona (PCB) and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the PCB with an occupy area of 5.000m2.

Active projects

Title Fundin: Organism Call: Funding source Role
ICTS-2017-10-CIBER-2 Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperiment Ministerio de Economía, Industria y Competitividad (MINECO) Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) Coordinator
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U3

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

27 Jan

Smart-4-Fabry final workshop

Next Wedneday, February 3, 2021 will take place the on-line event Smart-4-Fabry Final Workshop.   Smart-4-Fabry is a european project, coordinated by CIBER-BBN wich has been developed during four years. This project is a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages. This project is also a clear example of the relevance of access to advanced research infrastructures as NANBIOSIS -ICTS. Four NANBIOSIS units have collaborated and contributed to Smart-4-Fabry development: U1 Protein Production Platform (PPP) at IBB-UABU3 Synthesis of Peptides Unit at IQAC-CSICU6 Biomaterial Processing and Nanostructuring Unit at ICMAB-CSICU20 In Vivo[...]

22 Oct

Researchers of NANBIOSIS U3 working in a project to develop molecules with neutralizing properties of SARS-CoV-2

The research group of Chemical Multivalent Systems for Nanomedicine and NANBIOSIS U3 Sinthesys of Peptides Unit, of IQAC-CSIC and CIBER-BBN, participates in a new project that seeks to develop molecules with neutralizing properties of SARS-CoV-2, the cause of the COVID-19 disease, for the treatment of patients requiring hospitalization and clinical supervision due to the severity of the infection. The project, led by the Public University of Navarra (UPNA) and Navarrabiomed, counts with the participation of researchers from institute of advanced chemistry of catalonia (Institute of Advanced Chemistry of Catalonia), IRB Barcelona (Institute for Biomedical Research), CIBER-BBN (Center for Networked Biomedica[...]

21 Sep

NANBIOSIS Expertise in the IQAC-CSIC Symposium dedicated to the fight against Covid-19 Pandemic

The 4th Annual IQAC Symposium will take place on September 23, 2020. This year will be dedicated to the research projects on COVID-19 that are being carried out in the IQAC-CSIC. It will be a dissemination day aiming to inform the general public about some of the lines of research that are currently being developed in the fight against the COVID-19 pandemic. The event will be live streamed in Facebook: facebook.com/iqac.csic.es/ Three of the speakers, members of CIBER-BBN NANBIOSIS units at IQAC-CSIC, will explain their work. Pilar Marco and Roger Galve (NANBIOSIS U2 Custom Antibody Service (CAbS) will talk about[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

27 May

Peptide‐Capped Mesoporous Nanoparticles: Toward a more Efficient Internalization of Alendronate.

Osteoporosis is an illness which appears when the osteoblast/osteoclast activities are unbalanced taking place bone resorption (caused by osteoclasts) in higher extension than bone formation (induced by osteoblasts). Alendronate is one of the most used drugs for osteoporosis treatment despite its scarce bioavailability. In an attempt to improve it, gated mesoporous silica nanoparticles, for the controlled release of alendronate, have been synthesized and characterized. These hybrid nanoparticles include labelled alendronate inside the porous, those porous are capped with a peptide designed to be selectively cleaved by cathepsin K enzyme (overexpressed in osteoclasts). Two CIBER-BBN units of the ICTS NANBIOSIS wer[...]

16 Apr

A new strategy to synthesize Chol-PEG “on demand”

Researchers of NANBIOSIS U3 Synthesis of Peptides Unit of CIBER-BBN at IQAC-CSIC, led by Miriam Royo, have published an article in the scientific journal ACS Omega that develops a method for the production of cholesterol conjugates to peptide ligands through polyethylene glycol (ND-PEG) not dispersed through a non-hydrolyzable bond. The developed methodology allows to generate stable, highly pure and well defined Chol-PEG compounds, linked to different lengths of PEG from 4 to 20 units of ethylene oxide through an ether bond. These Chol-PEG compounds were conjugated with different peptides, such as cyclic peptide (RGDfK), gluturation and a Tf1R peptide ligand,[...]

U3-Synthesis of Peptides Unit
Read More

U4. Biodeposition and Biodetection Unit

Ciber bbn

U4. Biodeposition and Biodetection Unit

  • Scientific Director: Prof. Laura Lechuga laura.lechuga@icn2.cat
  • Scientific Coordinator: Dr. MªCarmen Estevez mcarmen.estevez@icn2.cat
  • Entities: Research Center on Nanoscience and Nanotechnology CIN2 & CSIC
  • Address: Campus Bellaterra, 08193 Cerdanyola del Vallés, Barcelona, Spain
  • Service Contact mail: nanob2a@icn2.cat
  • Phone: +34 937 374 617
  • Web: CIN2

CIN2_U4 CSIC

Order request

Description

Located at the Research Center onNanoscience and Nanotechnology(CIN2), CSIC, at the campus of Universidad Autónoma de Barcelona (UAB) the Biodeposition Unit consists of a versatile and automated molecular printer that can dispense minute volumes of solutions (from atto to femtoliter volumes) on a wide variety of surfaces to create user-defined patterns of spots or lines with high spatial resolution. The system is suitable for the functionalization of biosensors with any kind of biomolecule, nanoparticles, graphene or other nanostructures,for surface patterning for cell culture, or for the preparation of micro/nanoarrays, among other applications. The laboratory also harbors a Surface Plasmon Resonance (SPR) service. The Unit is coordinated by Prof. LauraM. Lechuga, group leader from the Nanobiosensorsand Bioanalytical Applications Group (nanoB2A) at CIN2-CSIC.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U4. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
H2020-ICT-2014-1 - 644956 Scalable point-of-care and label free microarray platform for rapid detection of sepsis Comisión Europea Others
TEC2016-78515-R Point-of-care Nanoplasmonic Platforms for Novel High-Value Diagnostics and Therapy Follow-Up (PreDICT) MINECO Others

Publications

2016

  • Avino A., Huertas C.S., Lechuga L.M., Eritja R.. Sensitive and label-free detection of miRNA-145 by triplex formation. Analytical and Bioanalytical Chemistry. 2016;:1-9.

News U4

16 Dec

Three Nanbiosis units work in the development of new sensors for the better detection of the fungus P. jirovecii, responsible for Pneumocystis pneumonia

Researchers from the CIBER-BBN have succeeded in developing detection systems for Pneumocystis jirovecii, an atypical fungus responsible for very serious pneumonia in immunosuppressed patients. These results, published in the journal Nanomaterials, are the result of collaboration between the CIBER-BBN groups led by Laura Lechuga, Ramon Eritja and Ramón Martínez Máñez, and the CIBERESP group led by Enrique J. Calderón. The researchers acknowledge the paricipation of three NANBIOSIS units of CIBER-BBN: Nanbiosis U29 Oligonucleotide Synthesis Platform (OSP), led by Ramon Eritja and Anna Avinó at IQAC-CSIC and Nanbiosis U4 Biodeposition and Biodetection Unit , led by Laura Lechuga at ICN2-CSIC, andNanbiosis[...]

30 Nov

2020 Rei Jaume I Awards ceremony – Laura Lechuga NANBIOSIS U4-

This monday 30 of october has taken place the traditional ceremony of Rei Jaume I Awards in Valencia, granted to six professionals in research, science and economics. At the ceremony, the awards have been given to the winners of the six categories: Rei Jaume I Basic Research Prize 2020 to Fco. José García Vidal; Rei Jaume I Economy Prize 2020 to Diego Puga; Rei Jaume I Medical Research Prize 2020 to Miguel Beato del Rosal; Rei Jaume I Environmental Protection Award 2020 to Fernando T. Maestre; Rei Jaume I New Technologies Award 2020 to Laura Lechuga and Rei Jaume I[...]

23 Nov

NANBIOSIS-ICTS AT CASEIB 2020

The XXXVII Annual Congress of the Spanish Society of Biomedical Engineering (CASEIB) is taking place between November 25 and 27. This new edition of CASEIB, in virtual format is organized by the CIBER-BBN group of Biomedical Engineering at Valladolid Universitiy, led by Prof. Roberto Sánchez Hornero. Prof. Laura Lechuga, Scientific Director of NANBIOSIS U4 Biodeposition and Biodetection Unit, member of the advisoty committee of scientific experts (Multidisciplinary Working Group) to the Ministry of Science and Innovation in COVID-19 and coordinator of the European project CONVAT shall participate in the Roundtable I: Biomedical Engineering and COVID-19 November 26, 12:00 h Researchers of BSICoS[...]

16 Nov

Laura Lechuga: awarded the most important recognition in Spain in the field of scientific research

The Scientific Director of NANBIOSIS U4 Biodeposition and Biodetection Unit Laura Lechuga, has been awarded the 2020 National Research Prize, the most important recognition in Spain in the field of scientific research, granted by the Ministry of Science and Innovation. The National Research Awards, created in 1982, aim to distinguish the merit of those researchers of Spanish nationality who are carrying out outstanding work in scientific fields of international relevance and who exceptionally contribute to the advancement of science, to the transfer of technology and the progress of humanity. These awards have a total amount of 300,000 euros, (30,000 euros[...]

20 Oct

Laura Lechuga awarded the 2020 Rei Jaume I Prize in New Technologies

The Valencian Government (Generalitat Valenciana), together with the Foundation Premios Rei Jaume I, announced today the awardees of the 32th edition of the Rei Jaume I Awards, one of the highest recognitions for a research career in Spain. Prof. Laura M. Lechuga Gomez, Full Professor of the Spanish National Research Council (CSIC), head of the NANBIOSIS U4 Biodeposition and Biodetection Unit  and the Nanobiosensors and Bioanalytical Applications Group (of CIBER-BBN and the ICN2), has received the New Technologies Award. Prof. Laura M. Lechuga received her PhD in Chemistry from the University Complutense of Madrid (Spain) in 1992. The principal focus of her researc[...]

18 Oct

Women Technologist Ada Byron Award to Laura Lechuga, Scientific Director of NANBIOSIS U4.

The organizing committee and jury of the seventh edition of the Ada Byron Prize for Technological Women, from the Faculty of Engineering of the University of Deusto, have awarded the 2020 award to Prof. Laura Lechuga Scientific Director of Nanbiosis U4 Biodeposition and Biodetection Unit of ICN2-CSIC and CIBER-BBN. Laura Lechuga has a degree in Chemical Sciences and is currently a research professor at the CSIC of Barcelona, Head of the Group of Nanobiosensors and Bioanalytical Applications. Her research area focuses on Nanomedicine, Nanodiagnosis and the technological development of nanophotonic biosensors and their integration into portable Point-of-Care (POC) platforms, as[...]

23 Sep

How Nanophotonic Label-Free Biosensors Can Contribute to Rapid and Massive Diagnostics of Respiratory Virus Infections: COVID-19 Case

An accurate and explanatory review recently published in ACS Sensors. led by Prof. Laura Lechuga, Scientific Director of Nanbiosis U4 Biodeposition and Biodetection Unit from CIBER-BBN and ICN2, discusses current diagnostic techniques for COVID-19 and possible future developments in this field. In particular, after highlighting the advantages and limitations of the methods available at present, the article introduces optical biosensors and illustrates how nanophotonic label-free devices can contribute to meet the emerging needs in this context. For further information at ICN2 website Reference article: Maria Soler, Maria Carmen Estevez, Maria Cardenosa-Rubio, Alejandro Astua, and Laura M. Lechuga, How Nanophotonic Label-Free Biosensors Can Contribute to Rapid and Massive Diagnostics of Respiratory[...]

24 Aug

Upgrade of UV / Ozone cleaner for NanoeNabler
NANBIOSIS U4 expands its capabilities with a upgrades

NANBIOSIS, U4 Biodeposition and Biodetection Unit has expanded its capabilities with two upgrades: Upgrade of UV / Ozone cleaner for NanoeNabler and Upgrade of the optics and the microfluidic components of the Biodetection Unit (SPR biosensor) This upgrade and new equipment have been confinanced by the European Regional Development Fund (ERDF) through the Plurirregional Operational Program of Spain (POPE)2014-2020[...]

U4-Biodeposition and Biodetection Unit
Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

    • Scientific Coordinator: Dr. Nathaly Segovia nvsegovia@icmab.es
    • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
    • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
    • Phone: +34 935 801 853
    • Fax: +34 935 805 729
    • Web: ICMAB

ICMAB CSIC

Order request

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Professor Jaume Veciana and Prof. Nora Ventosa, current directors of NANOMOL Group, which is a research group with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties.  It gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure. One example of Key-Enabling-Technology (KET) available in this unit is a simple one-step methodology, DELOS-SUSP, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supra­molecular organization and crystalline purity). This example shows one of the singularities of this unit is that counts with CF–based plants at different scales, from mL to L, which allow process development by QbD and process scale-up.
 

 

U6. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
H2020-MSCA-ITN-2014-642196 Integrated self-assembled SWITCHable systems and materials: towards responsive organic electronics - a multi-site innovative training action i-Switch Unión Europea H2020 Participant
2014 SGR 17 Consolidation Research Group: Molecular Nanociènciai Materials Orgànics (NANOMOL) Generalitat de Catalunya Participant
CTQ2013-40480-R Molecular Bio- and Electro-active materials for the improvement of health and social well-being (Be-Well) MICINN Participant
FP7-PEOPLE-2013-ITN nº 607721 Nanochemistry of molecular materials for 2-photon functional applications. Nano2Fun Unión Europea Participant
MAT2013-50036-EXP Cell Surface Vessel Engineering Using Dynamic Molecular Bioinfecting (DYNAMO) MINECO Participant
RTC-2016-4567-1 Nanocapsules containing active ingredients for the topical treatment of dermatological diseases (NANO4DERM) MINECO Participant
RTC-2014-2183-S Application of Quatsomes technology for the development of a new range of perfumed softeners with lower environmental impact MINECO Participant
201260E080 Self-assembly, Nanostructuring and Processing of Functional Organic Molecules and their Applications Ministerio de Ciencia e Innovación Participant
MAT2016-80826-R Molecular materials and supramolecular organizations for therapy, diagnosis and tissue engineering (MOTHER) MINECO Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Munoz-Gomez J.L., Monteagudo E., Lloveras V., Parella T., Veciana J., Vidal-Gancedo J.. Optimized polarization build-up times in dissolution DNP-NMR using a benzyl amino derivative of BDPA. RSC Advances. 2016;6(32):27077-27082.
  • Cordoba A., Hierro-Oliva M., Pacha-Olivenza M.A., Fernandez-Calderon M.C., Perello J., Isern B. et al. Direct Covalent Grafting of Phytate to Titanium Surfaces through Ti-O-P Bonding Shows Bone Stimulating Surface Properties and Decreased Bacterial Adhesion. ACS Applied Materials and Interfaces. 2016;8(18):11326-11335.
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.

News U6

26 Mar

A new european infrastructure will facilitate the transfer of nano-pharmaceuticals from the lab to the clinic

Launch of the cross-european PHOENIX project, which will provide a new infrastructure available to research laboratories, SMEs and start-ups to facilitate the transfer of nano-pharmaceuticals from the laboratory to clinical practice. PHOENIX will have a duration of 4 years and a total budget of 14.45 million euros. Two CSIC Institutes, ICMAB (CSIC) and INMA (CSIC-UNIZAR), and one CSIC spin-off, Nanomol Technologies, participate in the project, will count with the expertise of NANBIOSIS unit 6 (from CIBER-BBN and ICMAB-CSIC), led by Nora Ventosa. PHOENIX is an innovation project funded by EU’s Horizon2020 Framework Programme aimed to provide services for the development, characterization, testing,[...]

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

27 Jan

Smart-4-Fabry final workshop

Next Wedneday, February 3, 2021 will take place the on-line event Smart-4-Fabry Final Workshop.   Smart-4-Fabry is a european project, coordinated by CIBER-BBN wich has been developed during four years. This project is a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages. This project is also a clear example of the relevance of access to advanced research infrastructures as NANBIOSIS -ICTS. Four NANBIOSIS units have collaborated and contributed to Smart-4-Fabry development: U1 Protein Production Platform (PPP) at IBB-UABU3 Synthesis of Peptides Unit at IQAC-CSICU6 Biomaterial Processing and Nanostructuring Unit at ICMAB-CSICU20 In Vivo[...]

12 Dec

Mimicking lymph-nodes to proliferate T cells by Judith Guasch in Onda Cero Radio.

Judith Guasch, researcher from Nanomol group, coordinator of NANBIOSIS unit 6 of NANBIOSIS (CIBER-BBN / ICMAB-CSIC)  is interviewed in Onda Cero Radio  in the programme “De cero al infinito” con Paco de León, to talk about her recent research on hydrogels to mimic lymph nodes for cancer immunotherapy.  You can listen the interview to Judith Guasch in this link, from minute 11: 33 to minute 29:35. In her interview, Judith Guasch explains her research on hydrogels to mimic lymph modes to grow more effectively T cells for cancer immunotherapy, about the patent, the costs of the cancer immunotherapy, and about the 3D bio-printing and scaling[...]

26 Nov

Two new equipment items at the U6 of Nanbiosis with cofinancing from FEDER funds

The U6 of NANBIOSIS (Biomaterial Processing and Nanostructuring Unit) has expanded its capabilities with 2 new equipment items for the characterization unit. Both equipment items will allow the characterization of some physico-chemical properties of different nanomaterials. The Zetasizer ULTRA is used to measure the particle size of dispersed systems from sub-nanometer to several micrometers in diameter, using the technique of Dynamic Light Scattering (DLS). Zetasizer systems are also used to analyze particle mobility and charge (Zeta potential) using the technique of Electrophoretic Light Scattering (ELS), and the molecular weight of particles in solution using Static Light Scattering (SLS). The Green[...]

12 Nov

Third edition of the course on “Characterization techniques for Particulate Materials” with Amable Bernabé

The Soft Matrials Lab at ICMAB-CSIC, run by Amable Bernabé (NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit, hosted from Monday, 5 October, to Wednesday, 7 October a course on “Characterization techniques for particulate materials”. The course was an introduction to different techniques to characterize nanoparticles and other particulate matter, including the basic fundamentals, sample preparation, practical examples and results interpretation.  Due to the COVID-19 pandemic, the participants of the course were less than in previous years, and during the practical sessions the group was divided, so less people was at the same time inside the lab, and the safety measures could be kept.  Theory: Dynamic Light[...]

19 Oct

Novel Quatsome nanovesicles, prepared using compressed CO2, for the development of advanced nanomedicines

Guillem Vargas Nadal, researcher at Nanomol Group – NANBIOSIS U6 (ICMAB-CSIC and CIBER-BBN) and Nanomol Technologies will defend his PhD thesis on Friday, 23 October 2020, at 11 am in an online session. The PhD Thesis Defense will be held by videoconference from the ICMAB Meeting Room.  Further information and Registration to attend the PhD Thesis defense via Zoom nanoparticles at ICMAB-website. Supervisors: Nora Ventosa (Scientific Director of NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit and leader of Nanomol Group of CIBER-BBNLidia Ferrer (Nanomol Technologies S.L.) Abstract: The nanovesicles are being developed and investigated to be used in the pharmaceutical world to deliver drug and detect[...]

U6-Biomaterial Processing and Nanostructuring Unit
Read More

U7. Nanotechnology Unit

Ciber bbn

U7. Nanotechnology Unit

IBEC

Order request

Description

The Nanotechnology Platform is part of the institute’s long-term strategic plan to create new Core Facilities in nanofabrication and bionanocharacterization. Currently, the platform is an accessible and versatile research facility featuring 150m2 of class 10,000 cleanroom space and laboratories offering state-of-the-art equipment for the fabrication and characterization of micro- and nanodevices and structures. Our aim is to facilitate advanced research by providing services in the fields of nanoscience and nanotechnology for all academic and industrial researchers. Some of the many areas of application include nanobioengineering, BioMEMS, materials science, tissue engineering, optic and biomaterials. IBEC’s Nanotechnology Platform offers scientific and technological support that includes the design, development and analysis of devices, materials, and processes, so that academic researchers and companies alike may use the platform to develop their innovative ideas.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
TEC2015-70104-P Microscrofidic 3D platform of Neuronal culture compartmentalized for the study of neurological diseases MINECO Others
COMRDI15-1-0013-09 Advancecat: acceleradora pel desenvolupament de terapies avançades ACCIÓ Participant

Publications

2016

  • Lagunas A., Tsintzou I., Vida Y., Collado D., Perez-Inestrosa E., Pereira C.R. et al. Tailoring RGD local surface density at the nanoscale toward adult stem cell chondrogenic commitment. Nano Research. 2016;:1-13.

News U7

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

22 Jul

The Scientific Director of NANBIOSIS Unit 7, awarded with the Narcís Monturiol medal for his contribution to science and technology

The Catalan Government announced yesterday the Narcís Monturiol Medal award for scientific and technological merit to the Director of NANBIOSIS Unit 7 Nanotechnology Unit from CIBER-BBN and IBEC, Josep Samitier Martí, for his contribution to the development of the Catalan system of science and technology. The Narcís Monturiol Prize was established by the Generalitat of Catalonia in 1982, in honor of the Catalan scientist and inventor Narciso Monturiol, to award the people and entities that have made an outstanding contribution to the scientific and technological progress of Catalonia. It is awarded in the form of medals and plaques. The medals[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

04 Dec

“Tips and tricks to achieve good results at the bench”

The IBEC Core Facilities team, coordinating NANBIOSIS U7 Nanotechnology Unit has celebrated the 6th edition of the Workshop “Tips and tricks to achieve good results at the bench”. This workshop is focused on fundamental basic aspects of working in a Chemistry/Biology laboratory: process of performing an experiment, from previous planning until the moment of leaving the bench. The workshop was divided in two parts: Introduction and overview to the Good Laboratory  Practices.Highly interactive and practical daily lab situations with real equipment. Upon completion of this workshop participants are able to understand the basics of good laboratory practices, plan an experiment[...]

25 Nov

Agreement signed with MINECO for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, a project related to the ICTS NANBIOSIS has been selected by the Ministry of Science, Innovation and Universities for co-financing with FEDER funds of the European Regional Development Funds program. An agreement has been signed between the Ministry of Science, Innovation and Universities and the Institute of Bioingeniería of Catalonia (IBEC) for the implementation of the project “Mask Aligner Team for the unit of Nanotechnology (U7) of Nanbiosis” cofinanced by FEDER Performance Program 2014-2020.  The total budget of the project amounts to € 117.000, with 50% financing with FEDER Funds. IBEC isprocessing t[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

06 Feb

STRYKER & NANBIOSIS start a promising line of biomedical research collaboration

On January 23-24th a two-day meeting between NANBIOSIS and Stryker Trauma GmbH, took place at the Carlos III Health Institute, in Madrid, to explore synergies and potential joint initiatives.   Nils Reimers and Robin Buescher from Stryker, presented some of their research and upcoming projects in the field of trauma medical devices, and representatives from NANBIOSIS’ units -Marisa González from U16 Surface Characterization and Calorimetry Unit, Teresa Galán from U7, Nanotechnology Unit, Gemma Pascual from U17 Confocal Microscopy Service, from CIBER-BBN, Marisa García from U28 (Bionand) and José Francisco Guillén and Francisco Sanchez Margallo from the units of the Jesús[...]

03 Aug

Nanopatterns of Surface-Bound EphrinB1 Produce Multivalent Ligand–Receptor Interactions That Tune EphB2 Receptor Clustering

Researchers  of NANBIOSIS U7. Nanotechnology Unit, are coauthors of the article “Nanopatterns of Surface-Bound EphrinB1 Produce Multivalent Ligand–Receptor Interactions That Tune EphB2 Receptor Clustering” published by NanoLetters, ACC Publications. The authors present a nanostructured surface able to produce multivalent interactions between surface-bound ephrinB1 ligands and membrane EphB2 receptors. They have created ephrinB1 nanopatterns of regular size (<30 nm in diameter) by using self-assembled diblock copolymers. Next, they have used a statistically enhanced version of the Number and Brightness technique, which can discriminate—with molecular sensitivity—the oligomeric states of diffusive species to quantitatively track the EphB2 receptor oligomerization process in real time. The results[...]

U7-Nanotechnology Unit
Read More

U8. Micro – Nano Technology Unit

Ciber bbn

U8. Micro – Nano Technology Unit

  • Scientific Director: Dr. Rosa Villa rosa.villa@imb-cnm.csic.es
  • Scientific Coordinator: Dr. Xavier Illa xavier.illa@imb-cnm.csic.es
  • Entities: Instituto de Microelectrónica de Barcelona – Centro Nacional de Microelectrónica (IMB-CNM, CSIC)
  • Address: Campus UAB, 08193, Cerdanyola del Vallés, Barcelona, Spain
  • Phone: +34 935 947 700 ext. 1208
  • Web: IMB – CNM, CSIC

CNM CSIC

Order request

Description

This Micro-Nano Technologies Unit is located in the Microelectronic Institute of Barcelona, (IMB-CNM, CSIC) and it is coordinated by Dra Rosa Villa.

The unit has the capacity for producing high quality CVD-graphene and, thanks to the integration of the unit in the clean room facilities of the IMB-CNM*, it is possible to complete a wide range of micro- and nanofabrication processes (thermal processes and CVD, metallization, photolithography, dry and wet etching, etc.) for the complete fabrication of graphene-based microdevices. The unit also comprises the equipment that allow the fabrication of such devices in flexible substrates like Polyimide and Parylene to build biocompatible implants and neuroprosthesis. In addition, the unit has the capacity for the encapsulation and electrical characterization of the fabricated devices.

The clean-room facility of the IMB-CNM is the largest installation with micro-nano technologies facilities in Spain. Its 1500 m2 Clean Room classes 10 to 10,000 are part of the MICRONANOFABS network, considered as Singular Scientific-Technical Infrastructure (ICTS).

.

U8. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 696656
Graphene-based disruptive technologies — GrapheneCore1
Unión Europea (Comisión Europea) H2020-Adhoc-2014-20 Partner
GA: 785219 Graphene Flagship Core Project-2 — GrapheneCore2’
Unión Europea (Comisión Europea) H202-SGA-FET-GRAPHENE-2017 Partner
GA: 649953 GRAPHENE FPA – FLAGSHIP - Graphene-based revolutions in ICT and beyond Unión Europea (Comisión Europea) H2020-FETFLAG-2014 Partner
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2014-62114-EXP RUPTURE OF THE HEMATORRETINIAN BARRIER: CAUSE OR CONSEQUENCE OF THE DIABETIC RETINOPATHY? MINECO Others
BIO2014-61377-EXP BIOLIVER: THE DECONSTRUCTION APPLIED TO HEPATOLOGY MINECO Others
H2020-Adhoc-2014-20 - 696656 GrapheneCore1 European Commission Participant
FP7-ICT-2013-FET-F - 604391 Neurographene: Neurological Recordings with Graphene EUROPEAN COMISSION Others
IMI Grant agreement No 115902 Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS) Others

Publications

2016

  • Moya A., Sowade E., del Campo F.J., Mitra K.Y., Ramon E., Villa R. et al. All-inkjet-printed dissolved oxygen sensors on flexible plastic substrates. Organic Electronics: physics, materials, applications. 2016;39:168-176.
  • Yeste J., Illa X., Gutierrez C., Sole M., Guimera A., Villa R.. Geometric correction factor for transepithelial electrical resistance measurements in transwell and microfluidic cell cultures. Journal of Physics D: Applied Physics. 2016;49(37):-.
  • Hernando A., Lazaro J., Gil E., Arza A., Garzon J.M., Lopez-Anton R. et al. Inclusion of Respiratory Frequency Information in Heart Rate Variability Analysis for Stress Assessment. IEEE Journal of Biomedical and Health Informatics. 2016;20(4):1016-1025.

News U8

09 Apr

New organ-on-chip models provide new information for targeted treatments in personalised medicine

Xavi Illa, Gemma Gabriel, Mar Alvarez and Rosa Villa, researchers of NANBIOSIS ICTS U8 Micro– Nano Technology Unit (from CIBER-BBN and the IMB-CNM-CSIC). are co-authors of two reviews that summarise the latest efforts in organ-on-chip technologies to emulate in vitro microfluidic systems. These devices are an opportunity to evolve the fields of biofabrication and sensing technology. Organ-on-chip (OOC) technology has been an efficient tool in modern research to substitute laboratory mice and simulate tissue and organ-level physiology and function. In particular, these in vitro devices have been extensively applied to model the intestine, enhancing the research community’s knowledge about intestina[...]

11 Mar

Modulation of intercolumnar synchronization by endogenous electric fields in cerebral cortex with neuroprobes by NANBIOSIS unit 8

The collaboration of NANBIOSIS U8 Micro–Nano Technology Unit of the CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN) at the IMB-CNM in the research carried out by scientist of Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Université Paris-Saclay, Centre National de la Recherche Scientifique (CNRS) and ICREA has bien acknowledged in the publication of the results by Science Advances. Rosa Villa and Xavi Illa have been in charge of the fabrication of the probes used, more specifically, neuroprobes were designed and manufactured with 16 Ti / Au microelectrodes (20 / 200nm) on flexible polyimide substrates with open areas to improv[...]

03 Mar

Graphene sensors read low-frequency neural waves associated with distinct brain states

Xavier Illa, Anton Guimrea y Eduard Masvidal, researchers of the CIBER-BBN group GAB Lab at IMB-CNM led by Rosa Villa, are coauthors of a study recently published in “Nature Communication”, in which it is demonstrated that graphene-based active sensor arrays are a mature technology for large-scale application in wide frequency band neural sensing interfaces. NANBIOSIS U8 Micro– Nano Technology Unit has been used in the development of the research. This research has been carruied out within the framework of the European Project “Graphene Flagship. The scientists have developed a sensor based on CVD graphene that detects brain signals in a wide frequency[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

24 Jan

Hybridization of men and machines, with Rosa Villa

Prof. Rosa Villa, Scientific Director of NANBIOSIS U8 Micro– Nano Technology Unit, and group leader of the research group of biomedical applications of ICNM–CSIC and CIBER-BBN, has participated in the program of National Radio of Spain “The Open Future: Biobots” led by Tato Puerto. Following the recent presentation by a team of American scientists of the design of “reprogrammable organisms”, halfway between a robot and a living being, that is, an extraordinary living machine made from frog cells, the program of National Radio of Spain called “Open Future” has dedicated a session to explain what are “Biobots” and to generat[...]

12 Jan

Graphene active sensor arrays for long-term and wireless mapping of wide frequency band epicortical brain activity

Researchers of Nanbiosis U8 Micro– Nano Technology Unit, from CIBER-BBN and IMB-CNM-CSCIC have published an article in Nature Communications on Graphene arrays for long-term and wireless mapping of epicortical brain activity. A collaborative work in the framework of the Brain Com and Graphene EU projects. The article mentions the participation of NANBIOSIS-ICTS. Graphene active sensors have demonstrated promising capabilities for the detection of electrophysiological signals in the brain. Their functional properties, together with their flexibility as well as their expected stability and biocompatibility have raised them as a promising building block for large-scale sensing neural interfaces. However, in order to[...]

10 Jan

Inkjet Priting Technology, Manufacture and validation of electrochemical sensors in medical applications

Miguel Zea, a member of the NANBIOSIS U8 Micro– Nano Technology Unit presents a video explaining his research is based on the manufacture and validation of electrochemical sensors in medical applications: –“Using InkJet printing I have made sensors in different plastics and paper. Also using a novel approach in each sensor. I have made two pH sensors using novel Platinum and polymer inks and also a cortisol sensor on paper”. With this video, Miguel Zea, participates in the second edition of ‘I investigate, I am CSIC’. It is a competition hold by The Spanish National Research Council (CSIC) for its[...]

18 Dec

Printed sensors, a low cost alternative for clinical detection

In today’s society there is a great interest in developing new technologies that allow low-cost mass manufacturing, also called “rapid prototyping” or “additive manufacturing”. Rapid prototyping includes technologies such as sterolithography, 3D printing, laser sintering or printed electronics, among others. All of these share digital design and manufacturing from the consecutive addition of layers, that is, techniques that allow creating almost any shape or geometric feature in a very fast time.Printed electronics consists of printing inks on different types of substrates such as textiles, plastics, papers or films to make them “smart”. This technique is presented as an alternative to[...]

U8-Micro-Nano Technology Unit
Read More

U9. Synthesis of Nanoparticles Unit

Ciber bbn

U9. Synthesis of Nanoparticles Unit

    • Entities: Institute of Nanoscience of Aragón (INA)
    • Address: R&D Building, Campus Río Ebro, Universidad de Zaragoza. C/Mariano Esquirl S/n, 50018, Zaragoza, Spain
    • Phone: 34 976 761000 ext. 3496

Nanabiosis-logo Universidad de Zarargoza-U9-U13-U27.

Order request

Description

This unit, integrated in the Nanostructured Films and Particles Group at the Institute of Nanoscience of Aragón (INA) coordinated by Dr. Jesús Santamaría, has as objective the synthesis of nanoparticles with applications in biomedicine. The unit provides an automated system for the synthesis of nanoparticles using laser-induced pyrolysis of chemical precursors in gas and/or aerosol phase, which enable either individual nanoparticles or biocompatible hybrid nanostructures to be produced in large quantities. In addition, this facility is able to draw on a wide range of nanoparticles fabrication technique, as well as having the necessary specialized personnel, to undertake exhaustive characterization of the microstructure, chemical composition, particles size and distribution of sizes, as well as magnetic, optical and colloidal properties and degree of biological functionality of the synthesized material.

U9. Services & Rates

Equipments

In addition to this there is immediate access to advanced electron microscopies (SEM, TEM, HRTEM, UHRTEM), as well as other surface analysis and characterization equipment (XPS, XRD, FTIR, magnetic characterization). The equipment available makes this Unit unique to produce a wide variety of nanoparticles, , inorganic, polymeric, or multifunctional hybrid nanocomposites.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
CTQ2014-52384-R INTELLIGENT APPLICATIONS BASED ON NANOSTRUCTURED FIBERS CONTAINING NATURAL BIOCIDES WITH PHARMACOKINETIC CONTROL OF THEIR RELEASE Ministerio de Economia y Competitividad Participant
CTQ2013-49068-C2-1-R MICROSYSTEMS BASED ON NANOSTRUCTURES WITH SPECIFIC PROPERTIES OF ADSORPTION AND SUPERFICIAL PLASMON, FOR DETECTION OF HIDDEN EXPLOSIVES AND AGENTS OF CHEMICAL WAR. Ministerio de Economia y Competitividad Participant
TARMAC TARMAC. New tools for the diagnosis and treatment of respiratory infectious diseases: pH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistence Ministerio de Economia y competitividad Participant
TARMAC/IQMA-UDM-UPV pH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistence CIBER-BBN-CIBERES-SEPAR Participant
H2020-MSCA-ITN-2016/H2020-MSCA-ITN-2016 European Training Network for Continuous Sonication and Microwave Reactors. Unión Europea Participant
H2020-SPIRE-2014-2015 ADREM / Adaptable Reactors for Resource- and Energy-Efficient Methane Valorisation Unión Europea Participant
I-2012/023 Development of a microfluidic platform to produce nanomaterials and assessment on new nanotechnology applications Unión Europea Participant
CTQ2016-77147-R NEW STRATEGIES FOR CO2 CONVERSION USING CATALYSTS UNDER ELECTROMAGNETIC RADIATION. MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDAD Participant
CTQ2016-79419-R ADVANCED ADSORPTION TECHNOLOGIES, SERS DETECTION AND CATALYSIS FOR CHEMICAL WAR MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDAD Participant
NANOHEDONISM A photo-triggered on-demand drug delivery system for chronic pain European Research Council Participant
I-2011/004 HECTOR- MICROWAVE-ASSISTED MICROREACTORS: DEVELOPMENT OF A HIGHLY EFFICIENT GAS PHASE CONTACTOR WITH DIRECT CATAYST HEATING Unión Europea Participant
FIS PI15/01118 Towards an advanced therapy of bone regeneration: tissue intermediates activated by infrared energy for the controlled expression of osteogenic and angiogenic factors INSTITUTO DE SALUD CARLOS III Others
AMBIT Animal Model of Bone Regeneration Induced by Tissue Intermediates Responsive to Near-Infrared Light Roche Farma Participant

Publications

2016

  • Sebastian V., Smith C.D., Jensen K.F.. Shape-controlled continuous synthesis of metal nanostructures. Nanoscale. 2016;8(14):7534-7543.

News U9

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

13 Dec

Ignacio García and Javier Bonet present their work on the CADENCE project in a one-minute video

Ignacio García and Javier Bonet, researchers from the Nanoporous Films and Particles (NFP) group and Nanbiosis U9 Synthesis of Nanoparticles Unit of the CIBER-BBN and the Institute of Nanoscience and Materials Science at the University of Zaragoza have presented their work on the CADENCE project in a video of a minute of duration that has been submitted to the #QueSigalaCiencia scientific dissemination contest promoted by the CIBER-BBN. #QueSigaLaCiencia is a campaign on social networks that wants to explain to society, from an optimistic perspective, the importance of research and the work carried out by the research staff of the CIBER.[...]

08 Dec

NANBIOSIS participation in the Technology and business Forum “Technological challenges derived from COVID-19”

The pandemic has led companies and researchers to reorient their plans and projects to meet the demands of society. Different examples of these new challenges will be seen at the next Technology and Business Forum on Thursday, December 10, covering from new tissues, better masks, diagnostic tests, epidemiological models and clinical equipment … All this, from an analysis both from the perspective industrial and research. The Technological and Business Forum is organized by the Aragón Engineering Research Institute (I3A), the SAMCA Chair of Technological Development, CEOE-Aragón and the Zaragoza Chamber. On this occasion, it will be held online and it[...]

08 Nov

Jesús Santamaría, Scientific Director of NANBIOSIS Unit 9, candidate to the Rectorate of the University of Zaragoza

Jesús Santamaría, Scientific Director of NANBIOSIS U9, Synthesis of Nanoparticles Unit, runs for the elections to the Rectorate of the University of Zaragoza. Jesús Santamaría Ramiro, professor in the Department of Chemical Engineering and Environmental Technologies, at the Faculty of Sciences, has presented his candidacy to the Rectorate of the University of Zaragoza this week. The opinion group Proyecto Unizar, the germ of this candidacy, has also been presented. Proyecto Unizar, which motto is “Another University is possible” includes more than 60 members of the university community and more than a hundred supporters, among them, several members of CIBER-BBN NANBIOSIS Units in[...]

17 Aug

The University of Zaragoza, in the elite of the 500 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, once again places the University of Zaragoza among the elite of the 500 best universities in the world. This indicator organizes up to 20,000 university centers worldwide. Among the keys that have been able to positively influence the results of the research, according to the Vice Chancellor for Prospect, Sustainability and Infrastructure of the University of Zaragoza, Francisco Serón, are the increase in public campus funding for four years as well as the quality of their Scientists. The University of Zaragoza houses[...]

15 Jul

Biocidal releasing dressings of natural origin to treat topical wounds and avoid antibiotic resistance

Researchers of NANBIOSIS U9 Synthesis of Nanoparticles Unit, of the CIBER-BBN at the University of Zaragoza, use thymol as a natural biocide, a component present in the essential oils of thyme and oregano, thus fighting against the predictions that in 2050 there will be more deaths from infections associated with antibiotic-resistant bacteria than from cancer. Some topical wounds caused by burns, by surgical procedures, diabetic foot ulcers, fistulas, pressure ulcers, etc. they can become infected and become chronic, rendering current treatments ineffective. Currently, the devitalized tissue is removed, the area is cleaned, it is drained and depending on the microbia[...]

25 Jun

NANBIOSIS scientists in Aragón, explain on TV their research againts coronavirus

The special program on the coronavirus pandemic  by “En Ruta con la Ciencia” of Aragón Televisión, analyzes different aspects of the disease with special attention to the work of Aragonese scientists. Among them, two  research groups that coordinate NANBIOSIS units 9 and 27. Starting at minute 44’45 ‘of the program, Doctor Jesús Lázaro, researcher of the BSICoS group of I3A-UZ and CIBER-BBN, led by Pablo Laguna, which coordinates NANBIOSIS U27 High Performance Computing Unit, explains his research. For almost 3 years, Jesús Lázaro had been working on a European project to develop a respiratory and heart rate monitoring system for[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

U9-Synthesis of Nanoparticles Unit
Read More

U10. Drug Formulation

Ciber bbn

U10. Drug Formulation

    • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
    • Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
    • Entities: Universidad del País Vasco (UPV/EHU)
    • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
    • Phone: +34 653593042
    • Fax: +34 945 013040
    • Web: NANOBIOCEL UPV/EHU

UPV-EHU

Order request

Description

Located at the Faculty of Pharmacy, University of the Basque Country (UPV), Campus of Vitoria, is led by Prof. José Luis Pedraz and consists of large laboratories for: cell culture, chromatography equipment, sample preparation and characterization and one specific for scale preparation of pharmaceutical formulations. This Unit has the capacity to design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA and vaccines using different methodologies based on micro and nano-medicine. The latter methodology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this unit. It counts with the most advanced equipment for micro and nano encapsulation.

The aim of the Unit is to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.

The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit counts with the most advanced equipment to cover the development for all the steps of the process.

One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency

U10. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
RTC-2016-4770-1 Development of a new bioadhesive for the treatment of Pterigium. Biotape
Ministerio de Economía, Industría y Competitividad (MINECO) Retos Colaboración 2016 Partner
RTC-2016-5451-1 Development of Bioprinting and Bioink systems for cartilage and bone repair
Ministerio de Economía, Industria y Competitividad (MINECO) Retos Colaboración 2016 Partner
GA: 783132 POSITION-II “A pilot line for the next generation of smart catheters and implants”
Electronic Component Systems for European Leadership Joint Undertaking (JU) - ECSEL JU H2020-ECSEL-2017-1-IA-two-stage Partner
GA: 645991 DRIVE – Diabetes-Reversing Implants for Enhanced viability and long-term efficacy Unión Europea (Comisión Europea) H2020-NMP-2014-two-stage Partner
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
RTC-2016-4770-1 DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2016-5451-1 DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2015-3303-1 Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS MINISTERIO DE ECONOMIA Y COMPETITIVIDAD

Publications

2016

  • Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
  • Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.

News U10

04 Mar

Reversing pulmonary fibrosis has been achieved in murine models with peptide-loaded nanoparticles

A new study with participation of NANBIOSIS Unit 10 Drug Formulation unit of CIBER-BBN and UPV/EHU, has succeeded in preventing and reversing pulmonary fibrosis in experimental models with PLGA / PEI nanoparticles loaded with the GSE4 peptide. These results are the first step to study its possible antifibrotic effect in patients with idiopathic pulmonary fibrosis [...]

26 Jan

New Center for Research in Advanced Pharmaceutical Development

The NanoBioCel Research group, led by Jose Luis Pedraz, from CIBER-BBN and UPV/EHU, group that coordinates the Unit U10 Drug Formulation of NANBIOSIS -ICTS, together with the Provincial Council of Álava and the Center for Technological Research and Development TECNALIA, have launched last Thursday, January 21, the new Center for Research in Advanced Pharmaceutical Development, [...]

28 Dec

Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality

Researchers of CIBER-BBN Units of NANBIOSIS: U29 Oligonucleotide Synthesis Platform (OSP) at IQAC_CSIC, led by Prof. Ramón Eritja and U10 Drug Formulation, at UPV-EHU, led by Prof José Luis Pedraz, are coauthors of an article published by International Journal of Pharmaceutics. Gene therapy strategies based on non-viral vectors are currently considered as a promising therapeutic option [...]

21 Nov

Moore4Medical a project to accelerate innovation in electronic medical devices

The NanoBioCell group, led by Prof. Jose Luis Pedraz, participates in the European project Moore4medical. A project to accelerate innovation in emergencing medical devices with open tecnhology platforms. The NanoBiocel group, will focus on the lyophilization process of biopharmaceuticals and their use in microfluidic devices The NanoBiocel research group of the University of the Basque [...]

19 Nov

Ainhoa González Pujana, NANBIOSIS U10, 2019 best doctoral thesis award by the Bioaraba Research Health Institute

The Bioaraba Health Research Institute has awarded Ainhoa ​​González Pujana, a researcher at NanoBioCell and the Nanbiosis Platform through the U10 Drug Formulation (from CIBER-BBN and UPV-EHU), the award for the best doctoral thesis 2019 at the XXI Bioaraba Research and Innovation Conference, held last November 5 in Vitoria-Gasteiz. Along with the recognition, the award [...]

13 Nov

How to delay vision loss in hereditary retinal dystrophies? Looking for the most effective and economical pharmacological nanotherapy

Researchers from the CIBER-BBN and NANBIOSIS are participating in a new project that aims to achieve the most effective, specific and economical pharmacological nanotherapy that allows delaying the death of retinal cells and subsequent loss of vision in hereditary retinal dystrophy. retinitis pigmentosa, regardless of the genetic defect causing the disease. In this project, coordinated [...]

11 Nov

Laura Saenz del Burgo, NANBIOSIS U10, award for the best emerging researcher at the XXI Bioaraba Research and Innovation Conference

The CIBER-BBN researcher at the University of the Basque Country (UPV-EHU), Laura Saenz del Burgo, received, within the framework of the XXI Bioaraba Research and Innovation Conference, the award for the “Best Emerging Researcher 2020”. The researcher of the NanoBioCel group of the UPV / EHU, who belongs to the CIBER BBN and the U10 [...]

10 Nov

Regenerating ankle joints with collagen- and gelatine-based implants

 TRIANKLE is an EU Project to develop regenerative therapies for ankel injuries in which participate NanoBioCell Group and NANBIOSIS U10 Drug Formulation unit (from CIBER-BBN and UPV/EHU), led by José Luis Pedraz. The main objective is to reduce the time of recovery down to 50% andincrease the functionality ratios up to 10-15%. Research consortium [...]

03 Jul

From natural by-products to cell delivery systems for regenerative medicine

Researchers from NANBIOSIS U10 Drug Formulation unit (CIBERBBN – UPV/EHU led Rosa María Hernández, have developed a biomedical device consisting of by-products from the food industry and which displays excellent properties for use in regenerative medicine. The work has been published in the Green Chemistry Jurnal, one of the most prestigious international journals in chemistry [...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research [...]

U10-Drug Formulation
Read More

U12. Nanostructured liquid characterization unit

Ciber bbn

U12. Nanostructured liquid characterization unit

    • Scientific Director: Prof. Carlos Rodríguez cranqb@cid.csic.es
    • Scientific Coordinator: Jordi Esquena jemqci@iqac.csic.es
    • Entities: Colloid and Interfacial Chemistry Group (QCI) at the Institute of Advanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
    • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
    • Phone: +34 934 006 159
    • Web: QCI – IQAC- CSIC

IQAC CSIC

Order request

Description

The unit is located at the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), in Barcelona and it is coordinated by the Colloidal and Interfacial Chemistry Group, led by Dr. Carlos Rodríguez. The unit is focused on the characterization of nanostructures in liquids and liquid/liquid interfaces, such as micelles, liposomes, micro- and nano-emulsions, and nanoparticles. The unit features state-of-the-art instrumentation for the determination of various parameters such as size distribution and zeta potential (surface charge), critical micelle concentration (CMC), solubilization capacity, osmolarity, surface and interfacial tension, wettability, refractive index, turbidity, colloidal stability, density, viscosity and other rheological parameters (shear and elastic moduli, critical yield stress, etc.)

U12. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
CTQ2014-52687-C3-1-P Design and applications of new biocompatible micro / nanogels obtained by advanced condensation methods (MICRONANOGELES) MINECO Participant
2014SGR1655 Grants for consolidated Research Groups of Catalonia Generalitat de Catalunya Participant
FP7-PEOPLE-2013-ITN - 606713 Biopolymer Based FOOd Delivery Systems (BIBAFOODS) Unión Europea Participant
Plan de Actuación 2015 Agreement of ACC1Ó with the UAB, the PRUAB, the CSIC and the CVC for the promotion of the technological transfer Generalitat de Catalunya Participant
TECSPR14-2-0033 Theranostic Magnetic Nanoparticles For Cancer Diagnosis and Treatment: Magnetic Properties and Controlled Release of Anticancer Drugs (TheraMagNano) Unión Europea Participant
TECSPR14-2-0044 Novel antimicrobial hydrogels for contact lenses (HYDROLENSES) Unión Europea Participant
Acción COST CM1101 Joint Meeting of WG 3 and WG 4. Workshop "Nano-biocolloidal materials and non-equilibrium self-assembly" Unión europea Participant
Ref.: 308810 076/2015 DEVELOPMENT OF INNOVATIVE FORMULATIONS FOR THE DELIVERY OF ACTIVITIES INTO THE SKIN (ES) ALMIRALL Participant

Publications

2016

  • Fornaguera C., Caldero G., Solans C.. Electrolytes as a tuning parameter to control nano-emulsion and nanoparticle size. RSC Advances. 2016;6(63):58203-58211.
  • Caldero G., Montes R., Llinas M., Garcia-Celma M.J., Porras M., Solans C.. Studies on the formation of polymeric nano-emulsions obtained via low-energy emulsification and their use as templates for drug delivery nanoparticle dispersions. Colloids and Surfaces B: Biointerfaces. 2016;145:922-931.
  • Fornaguera C., Feiner-Gracia N., Caldero G., Garcia-Celma M.J., Solans C.. PLGA nanoparticles from nano-emulsion templating as imaging agents: Versatile technology to obtain nanoparticles loaded with fluorescent dyes. Colloids and Surfaces B: Biointerfaces. 2016;147:201-209.
  • Magana J.R., Kolen’Ko Y.V., Deepak F.L., Solans C., Shrestha R.G., Hill J.P. et al. From Chromonic Self-Assembly to Hollow Carbon Nanofibers: Efficient Materials in Supercapacitor and Vapor-Sensing Applications. ACS Applied Materials and Interfaces. 2016;8(45):31231-31238.
  • Perez-Carrillo L.A., Vilchez S., Mosa J., Aparicio M., Castro Y., Duran A. et al. Synthesis and properties of TiO2-P2O5 and SiO2-TiO2-P2O5 porous hybrids obtained by templating in highly concentrated emulsions. Ceramics International. 2016;42(16):18965-18973.

News U12

18 Feb

Gels formed from the interaction of lipid vesicles: Influence of charge in their structural and rheological properties

Susana Vilchez, researcher at NANBIOSIS U12. Nanostructured liquid characterization unit  of CIBER-BBN and IQAC-CSIC, is coauthor of an article recently published in the Journal of Molecular Liquids. “This work – explains Susana Vilchez – shows how structural and viscoelastic properties of a lipid colloidal gel can be altered by varying the ratio of charged lipids in the dispersion. These findings corroborate that the eventual formation of the gel and the morphology of its network is governed by the repulsive potential of the particles instead of the molecular composition of their membranes. Thus, the right control of charge balance in the system may[...]

28 Jan

Encapsulation of BSA/alginate water–in–water emulsions by polyelectrolyte complexation

Researchers of NANBIOSIS U12. Nanostructured liquid characterization unit from CIBER-BBN and IQAC-CSIC have recently published an article entitled Encapsulation of BSA/alginate water–in–water emulsions by polyelectrolyte complexation in the scientific journal Food Hydrocolloids The research which results are published involves the encapsulation of drops of water-in-water emulsions, which could be used as vehicles for the administration of active principles. Characterization of emulsions and capsules was performed in the Unit 12 of NANBIOSIS Nanostructured Liquid Characterization Unit. Water-in-Water (W/W) emulsions were prepared in aqueous mixtures of an anionic polyelectrolyte (sodium alginate, NaAlg), with a globular protein (bovine serum albumin, BSA). This combination showed phase separation[...]

08 Jan

New Scanning Electron Microscope and on line Seminar to explain it for internal and external accesses on NANBIOSIS U12

A new Scanning Electron Microscope (Hitachi TM-4000 Plus II) has been installed at the Nanostructured liquid characterization unit of NANBIOSIS ICTS (Unit 12) of CIBER-BBN and IQAC-CSIC. An online seminar will be given by Susana Vilchez on January 14th at 12h to explain the various features, functions and capabilities of this new instrument, Tabletop Scanning Electron Microscope Hitachi TM-4000 Plus II, that is open for both internal and external users. Those interested in attending the seminar can contact unit 12 of NANBIOSIS: Scientific Director: Prof. Carlos Rodríguez cranqb@cid.csic.esScientific Coordinator: Jordi Esquena jemqci@iqac.csic.es[...]

25 Nov

NANBIOSIS U12 expands its capabilities with a new SEM for morphological and dimensional characterization of solid samples

The U12 of NANBIOSIS (Nanostructured liquid characterization unit) has expanded its capabilities with a new equipment U12-E22. SEM Hitachi TM4000Plus II for morphological and dimensional characterization of solid samples Low vacuum Scanning Electron Microscopy with two electron detectors (secondary, SE, and backscattered, BSE). SE imaging provides a detailed information of the morphology of the sample and BSE gives information about the different components of the sample, based on the different atomic number (the higher the atomic number, the brighter the surface). The equipment can apply different vacuum levels (using a turbo molecular pump) with accelerating voltages between 5 and 20[...]

30 Sep

NANBIOSIS U12 researchers modify contact lenses to reduce the risk of bacterial infection

Researchers from NANBIOSIS U12 Nanostructured liquid characterization unit, from CIBER-BBN at the IQAC-CSIC have chemically modified contact lenses, incorporating antibacterial properties. Contact lenses, especially soft ones, pose a risk of ocular microbial infection that can eventually lead to loss of vision. “These new contact lenses inhibit the formation of bacterial biofilms and could prevent ocular keratitis” explains Jordi Esquena, a researcher at the CIBER-BBN at the IQAC-CSIC and one of the coordinators of the work. In the study, published in Colloids and Surfaces B: Biointerfaces, bactericidal activity was introduced into hydrogel contact lenses, through antimicrobial peptides that were anchored on[...]

26 Apr

A Concise Review on Nano-emulsion Formation by the Phase Inversion Composition (PIC) Method

Researchers of NANBIOSIS U12. Nanostructured liquid characterization unit from CIBER-BBN and IQAC-CSIC have recently published an interesting review entitled “A Concise Review on Nano-emulsion Formation by the Phase Inversion Composition (PIC) Method” in the JOURNAL OF SURFACTANTS AND DETERGENTS. https://doi.org/10.1002/jsde.12414 Studies of phase behavior and particle sizing were performed at the Nanostructured Liquid Characterization Unit, member of the NANBIOSIS ICTS.[...]

07 Feb

Ethylcellulose nanoparticles as new “in vitro” tool for cell transfection

Researchers of NANBIOSIS U12 Nanostructured liquid characterization unit and U29 Oligonucleotide Synthesis Platform (OSP) of CIBER-BBN at IQAC-CSIC have obtained successfully ethylcellulose nanoparticles with positive zeta potential formed from nano-emulsion complexation with an antisense oligonucleotide which result very promising complexes for “in vitro” cell transfection. A new non-viral gene delivery vector has been developed, based on ethylcellulose, an easily available and low cost carbohydrate polymer, “generally recognized as safe” by the FDA. Although ethylcellulose is nonionic, positively charged nanoparticle dispersions have been obtained using nano-emulsion templates in cationic:non-ionic surfactant-based systems. The nanoparticles have been successfully complexed with negatively charged phosphorothioate antisens[...]

02 Dec

Carlos Rodriguez-Abreu (NANBIOSIS U12) keynote speaker in OKINAWA COLLOIDS 2019

Carlos Rodriguez-Abreu, Scientific Director of NANBIOSIS U12 Nanostructured liquid characterization unit has been invited speaker at OKINAWA COLLOIDS 2019 conference in Okinawa, Japan on November 3 to 8, 2019 in the session Foams / Bubbles / Emulsions and Microemulsions.Foams and emulsions stabilized by surfactants, amphiphilic polymers and solid particles are essential formulations for developing pharmaceuticals, cosmetics, foods and so on. Recently, many functional systems have been proposed including stimuli responsive materials, biocompatible materials, and environmental affinity materials. The topics of this session include a wide range of subjects: physical properties, phase behaviors and new functions of these systems.[...]

U12-Nanostructured liquid characterization unit
Read More